Meta-Analysis Comparing Potent Oral P2Y₁₂ Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

ABSTRACT:

Background

In patients with atrial fibrillation (AF) receiving percutaneous coronary intervention (PCI), current guidelines recommend against combining potent oral P2Y₁₂ inhibitors (i.e. ticagrelor or prasugrel) with oral anticoagulant (OAC) therapy, but the evidence is limited.

Objective

The aim of this meta-analysis was to compare the efficacy and safety of potent oral P2Y₁₂ inhibitors with clopidogrel in patients receiving OAC therapy for AF after a recent PCI.

Methods

Electronic databases were searched for randomized controlled trials (RCT) reporting outcomes according to the P2Y₁₂ inhibitor used. Major or clinically relevant non-major bleeding were the safety endpoints, while the efficacy outcomes were major adverse cardiovascular

SUBMITTER: Casula M 

PROVIDER: S-EPMC7956939 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature